Skip to main content
. 2016 Aug 16;6:31664. doi: 10.1038/srep31664

Figure 3. A JNK inhibitor, SP600125, attenuates MPT0G066-mediated JNK activity, regulatory proteins of G2/M and apoptotic pathway.

Figure 3

SKOV3 or A2780 cells were treated with 1 μM MPT0G066 with or without 20 μM SP600125 for (A–C) 24 h or (D) 48 h. The whole cell lysates of SKOV3 or A2780 were subject to western blot analysis with (A) phosphorylated JNK (Thr-183 and Tyr-185), (B) MPM-2, cyclin B1, total or phosphorylated cdc2 (Tyr-15 and Thr-161), total or phosphorylated cdc25c (Ser-216), aurora A, aurora B, total or phosphorylated PLK-1 (Thr-210), (C) total or phosphorylated Bcl-2 (Ser-70), (D) caspase-3 and PARP. Actin was served as a loading control. (E) SKOV3 or (F) A2780 cells were incubated with various concentrations of MPT0G066 (0.03–1 μM) with or without 20 μM SP600125 for 48 h. Cell viability was measured by MTT assay.